TL;DR
The current understanding of KMT and BHB in the context of ADPKD are summarized and their potential as safe, noninvasive, and disease-modifying interventions are discussed.
Current data suggest that L-carnitine supplementation may improve metabolic parameters, including insulin resistance and lipid profiles, while exerting antioxidant and anti-inflammatory effects in ovarian tissue, but clinical evidence is limited by heterogeneity in study design, small sample sizes, and reliance on surr...
KA/EAA-supplemented VLPD may delay kidney replacement therapy in appropriately selected and supervised patients, but the supplement should be prescribed as part of a complete nutritional strategy rather than as an autonomous drug.
A Multi-Hit Residual Renal Risk (MHR3) model is proposed in which evidence-based pharmacotherapy constitutes the therapeutic foundation and tocotrienols are positioned only as an investigational adjunct targeting incompletely controlled biological injury.
A 59-year-old man with obesity, type 2 diabetes, CKD stage 3b, albuminuria and established cardiovascular disease receiving optimized treatment with renin–angiotensin–aldosterone system blockade, sodium-glucose cotransporter-2 inhibition, semaglutide and finerenone develops symptomatic severe non-parathyroid hormone-me...
A narrative review synthesizes the current evidence on accelerated aging in PKU, describes its clinical manifestations, and proposes potential aging biomarkers and treatment targets.
Diabetic kidney disease (DKD) is among the most common and severe microvascular complications of diabetes and represents a leading cause of end-stage renal disease (ESRD) worldwide. Currently, although strict glycemic and blood pressure control, together with the use of renin–angiotensin system inhibitors, sodium-gluco...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
